Invention Grant
- Patent Title: Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
-
Application No.: US15106176Application Date: 2014-12-22
-
Publication No.: US10344080B2Publication Date: 2019-07-09
- Inventor: Jan Grimm , Aubin Michalon
- Applicant: Neurimmune Holding AG
- Applicant Address: CH Schlieren
- Assignee: Neurimmune Holding AG
- Current Assignee: Neurimmune Holding AG
- Current Assignee Address: CH Schlieren
- Agency: McDermott Will & Emery LLP
- Agent Kristina Bieker-Brady
- Priority: EP13199251 20131220
- International Application: PCT/EP2014/079094 WO 20141222
- International Announcement: WO2015/092077 WO 20150625
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K38/17 ; C07K16/18 ; G01N33/68

Abstract:
Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to antibodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
Public/Granted literature
- US20160355576A1 ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR Public/Granted day:2016-12-08
Information query